Stockscreener 앱 받기
1.97
8.84%
0.16
시간 외 거래:
1.96
-0.01
-0.51%
전일 마감가:
$1.81
열려 있는:
$1.91
하루 거래량:
279.97K
Relative Volume:
0.95
시가총액:
$12.05M
수익:
$1.38M
순이익/손실:
$-179.05M
주가수익비율:
-0.3208
EPS:
-6.14
순현금흐름:
$-155.03M
1주 성능:
+13.87%
1개월 성능:
+66.95%
6개월 성능:
+426.88%
1년 성능:
+68.38%
1일 변동 폭
$1.86
$2.00
1주일 범위
$1.69
$2.22
52주 변동 폭
$0.16
$6.83
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.97 | 12.05M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
Real-World Deployments Signal AI Healthcare Is Ready for Scale - FinancialContent
BioXcel Therapeutics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
BioXcel Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement - Revista ADVFN
BioXcel Therapeutics Receives Positive Recommendation from Data - GuruFocus
BTAIBioXcel Therapeutics Provides Clinical and Business Update - mx.advfn.com
BioXcel’s Phase 3 trial of BXCL501 continues as advised by DSMB - Investing.com India
BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq L - GuruFocus
BioXcel Therapeutics granted Nasdaq extension - Investing.com Australia
BioXcel granted an extension for compliance by Nasdaq - Hartford Business Journal
BioXcel Therapeutics granted Nasdaq extension By Investing.com - Investing.com South Africa
BTAI's Phase 3 Trial for BXCL501 Advances Unhindered by Safety Concerns | BTAI Stock News - GuruFocus
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated wit - GuruFocus
Bioxcel Therapeutics Granted Extension To Regain Compliance With Nasdaq Continued Listing Requirement - marketscreener.com
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq Listing - GuruFocus
BioXcel's Breakthrough At-Home Agitation Drug Clears Critical Safety Review, First FDA Approval Possible - Stock Titan
BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | B - GuruFocus
BioXcel Granted Nasdaq Compliance Extension Until September - TipRanks
BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | BTAI Stock News - GuruFocus
BioXcel Gets Critical Nasdaq Reprieve: 4-Month Extension as Phase 3 Trial Results Near - Stock Titan
BioXcel Therapeutics stock hits 52-week low at $0.3 - MSN
Can a $10,000 Investment in SoundHound AI Turn Into $1 Million by 2035? - The Globe and Mail
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options - The Globe and Mail
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments - TipRanks
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | BTAI Stock News - GuruFocus
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BioXcel Therapeutics (BTAI) Reports Major Milestone in BXCL501 T - GuruFocus
BioXcel Therapeutics Q1 2025 Financial Results and Business Update - TradingView
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight - The Malaysian Reserve
Press Release Distribution & PR Platform - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of BioXcel Therapeutics, Inc.(BTAI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
BioXcel Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
BioXcel Therapeutics stock hits 52-week low at $1.72 By Investing.com - Investing.com Canada
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오엑셀 테라퓨틱스 주식 (BTAI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mehta Vimal | CEO and President |
Dec 16 '24 |
Sale |
0.36 |
3,117 |
1,131 |
59,605 |
| Steinhart Richard I | Chief Financial Officer |
Dec 16 '24 |
Sale |
0.36 |
577 |
207 |
20,932 |
| Rodriguez Javier | See Remarks |
Dec 16 '24 |
Sale |
0.36 |
430 |
153 |
24,423 |
| Yocca Frank | Chief Scientific Officer |
Dec 16 '24 |
Sale |
0.35 |
430 |
152 |
28,931 |
0.39%
0.42%
자본화:
|
볼륨(24시간):